FMS 6-K
Fresenius Medical Care AG (FMS)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
For the month of May 2025
Commission file number: 001-32749
FRESENIUS MEDICAL CARE AG
(Translation of registrant's name into English)
Else-Kröner Strasse 1
61346 Bad Homburg
Germany
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
EXHIBITS
The following exhibits are being furnished with this Report:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
DATE: May 14, 2025
| Fresenius<br>Medical Care AG | |
|---|---|
| By: | /s/ Helen Giza |
| Name: | Helen Giza |
| Title: | Chief Executive Officer and Chair of the Management Board |
| By: | /s/ Martin Fischer |
| --- | --- |
| Name: | Martin Fischer |
| Title: | Chief Financial Officer and member of the Management Board |
Exhibit 99.1
Countermotions submitted by the Associationof Critical Shareholders (Dachverband der Kritischen Aktionärinnen und Aktionäre e.V.) for the Annual General Meeting of Fresenius Medical Care AG on May 22, 2025
Countermotion on Agenda Item 3: Resolution on the approval of actionsof the members of the Management Board of Fresenius Medical Care AG for fiscal year 2024
The Association of Critical Shareholders proposes that approval of actions is not granted to the members of the Management Board for fiscal year 2024.
Reason:
The Management Board fails to meet its obligations for good corporate governance.
The U.S. antitrust authority is investigating FMC
Fresenius Medical Care already came under scrutiny by U.S. competition authorities last year. According to a report by the U.S. magazine Politico, the Federal Trade Commission (FTC) is investigating suspicions that FMC and its competitor DaVita – the two dominant dialysis providers in the U.S. – may have unlawfully hindered smaller competitors. (cf.
https://www.politico.com/news/2024/07/13/feds-dialysis-giants-antitrust-probe-00167857)
According to the report, the FTC suspects that both companies made it unduly difficult for physicians working in their clinics to establish their own businesses or to move to competing providers. The non-compete agreements enforced by the companies reportedly affect nephrologists. The report also suggests that efforts to enable patients to receive treatment at home rather than in a clinic may have been obstructed. The FTC investigation is said to be in its early stages.
In the United States, more than 500,000 people receive dialysis treatment, which typically takes place three times a week. Diabetes is the most common cause of kidney failure.
FMC Clinics in Latin America Fall Victim to Cost-Cutting Program
As part of its comprehensive cost-cutting program, Fresenius Medical Care has sold clinics in Latin America as well as laboratory business units in the United States. According to Deutsches Ärzteblatt, this includes a total of 154 dialysis clinics in Brazil, Colombia, Chile, and Ecuador, employing more than 7,100 people. The sale of this clinic network is taking place, of all companies, to its competitor DaVita.
Strike by Dialysis Workers in California Over Union Busting
In October 2024, more than three dozen locations in the U.S. state of California saw a six-day strike due to union busting—systematic efforts to combat, suppress, and sabotage unions, employee representation, and works councils. This also affected Fresenius Medical Care (e.g., video: *"Strike of Dialysis Workers Across California "*https://www.youtube.com/watch?v=pJGfxI1UBfw).
Dialysis care workers, represented by the Service Employees International Union - United Healthcare Workers West, stated that their employers were violating healthcare workers' rights by retaliating against workers who speak out about poor working conditions and engaging in anti-union activities.
"Instead of treating us with respect and listening to our concerns, they are illegally attempting to break up our union to protect their profits. We want these unfair labor practices to end, and for our employer to respect our rights," said a nurse at the Fresenius Gateway Clinic in San Diego.
Cologne, May 7, 2025
www.kritischeaktionaere.de
Exhibit 99.2
Statement of the Management on the countermotion
of the Association of CriticalShareholders (Dachverband der Kritischen Aktionärinnen und Aktionäre e.V.)
to item 3 of the agenda of the Annual GeneralMeeting on May 22, 2025
The Management Board and the Supervisory Board stand by their proposed resolutions on the agenda and comment on the countermotion as follows:
Resolution on the approval of the actions of the Management Board for fiscal year 2024
The allegation in the countermotion that the Management Board is not fulfilling its obligation to good corporate governance is not true and is strongly rejected.
Fresenius Medical Care operates its business in a manner that is consistent with the antitrust laws in the United States and fully cooperates with the United States Federal Trade Commission in its inquiry regarding the company’s acquisition of Medical Director services or the provision of dialysis services.
Fresenius Medical Care announced several divestitures as part of its Legacy Portfolio Optimization program during fiscal year 2024. This also included the sale of its dialysis clinic networks in Brazil, Colombia, Chile and Ecuador to DaVita Inc. Fresenius Medical Care refocuses on businesses and markets with the best strategic fit and potential for sustainable growth and therefore exits unsustainable markets.
Fresenius Medical Care recognizes the freedom of association and the right to collective bargaining. The company complies with applicable laws and continues to bargain in good faith with the US union mentioned in the countermotion.